[Federal Register Volume 65, Number 211 (Tuesday, October 31, 2000)]
[Notices]
[Page 64974]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-27890]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent 
application referenced below may be obtained by contacting J. R. Dixon, 
Ph.D., at the Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; e-mail 
[email protected]). A signed Confidential Disclosure Agreement is required 
to receive a copy of any patent application.
    Entitled: ``USE OF 14-3-3 AS A DIAGNOSTIC MARKER AND 
THERAPEUTIC TARGET''--A Method to Diagnosis and Determine the Prognosis 
of Breast and/or Ovarian Cancers.
    Inventors: Drs. Olga Aprelikova (NCI) and Edison T. Liu (NCI) DHHS 
Ref. No. E-307-00/0, Filed with the USPTO on September 7, 2000.
    Breast cancer is one of the most significant cancerous diseases 
that affects women. At the current rate, American women have a 1 in 8 
risk of developing breast cancer by age 95 (American Cancer Society, 
1992). Treatment of breast cancer at later stages is often futile and 
disfiguring, making early detection a high priority in medical 
management of the disease. Ovarian cancer, although less frequent than 
breast cancer is often rapidly fatal and is the fourth most common 
cause of cancer mortality in American women. Genetic factors contribute 
to an ill-defined proportion of breast cancer incidence, estimated to 
be about 5% of all cases but approximately 25% of cases diagnosed 
before age 40. Breast cancer has been subdivided into two types, early-
age onset and late-age onset, based on an inflection in the age-
specific incidence curve around age 50. Mutation of one gene, BRCA1, is 
thought to account for approximately 45% of familial breast cancer, but 
at least 80% of families with both breast and ovarian cancer.
    The 14-3-3 checkpoint control gene is significantly 
downregulated in BRCA1 -/-cells. The cell cycle profile of these cells 
treated with ionizing radiation showed an inability to sustain G2/M 
growth arrest typical for 14-3-3 deprived cells. In addition, 
14-3-3 has been identified as a p53 inducible gene after DNA 
damage. Thus, BRCA1 synergistically activates p53 dependent 
transcription of 14-3-3 gene. These observations demonstrate 
the role of 14-3-3, and the interaction of BRCA1, p53, and 14-
3-3 in neoplastic conditions, such as breast cancer or ovarian 
cancer.
    The technology disclosed in the E-307-00/0 patent application is 
directed to a method to identify an agent that modulates 14-3-
3. The 14-3-3 checkpoint control gene is 
significantly downregulated in BRCA1 -/-cells. The method includes 
incubating the agent and a sample of interest, wherein the sample is 
capable of expressing 14-3-3, under conditions sufficient to 
allow the compound of interest to interact with the sample, and 
determining the effect of the compound on the expression or activity of 
14-3-3. The effect of an agent on the interaction of 14-3-
3 with p53 and/or BRCA1 can also be assessed. A method is also 
provided for determining the prognosis of a subject diagnosed with a 
14-3-3-associated disorder. The method includes contacting a 
sample from the subject with a reagent that binds to 14-3-3, 
detecting binding of the reagent to 14-3-3; and correlating 
the binding of the reagent to the sample with the prognosis of the 
disorder. The method can also include detecting p53 and/or BRCA1 
mutations.
    The above mentioned invention is available for licensing on an 
exclusive or non-exclusive basis.

    Dated: October 23, 2000.
Jack Spiegel,
Director, Division of Technology Development & Transfer, Office of 
Technology Transfer.
[FR Doc. 00-27890 Filed 10-30-00; 8:45 am]
BILLING CODE 4140-01-P